Clinical Relevance of Matrix Metalloproteinase-13 Determined with a New Highly Specific and Sensitive ELISA in Ascitic Fluid of Advanced Ovarian Carcinoma Patients
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 378853066 | ||
| 003 | CHVBK | ||
| 005 | 20180305123328.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 161128e20030820xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1515/BC.2003.137 |2 doi |
| 035 | |a (NATIONALLICENCE)gruyter-10.1515/BC.2003.137 | ||
| 245 | 0 | 0 | |a Clinical Relevance of Matrix Metalloproteinase-13 Determined with a New Highly Specific and Sensitive ELISA in Ascitic Fluid of Advanced Ovarian Carcinoma Patients |h [Elektronische Daten] |c [B. Hantke, N. Harbeck, B. Schmalfeldt, I. Claes, O. Hiller, M.-O. Luther, A. Welk, W. Kuhn, M. Schmitt, H. Tschesche, B. Muehlenweg] |
| 520 | 3 | |a Matrix metalloproteinases (MMPs) are involved in many physiological and pathophysiological processes, including tumor cell invasion and metastasis. For one member of this family, MMP-13 (collagenase-3), a new, highly specific ELISA with a sensitivity of 0.5 ng MMP-13/ml was established. The protein levels of MMP-13 in ascitic fluids of 30 patients with advanced ovarian cancer FIGO stage III (n=19) and IV (n=11) were measured with this ELISA. Using a cutoff value of 0.5 ng MMP-13/mg total protein, two patient subpopulations with short (median 16 months) and long (median 36 months) overall survival were identified. Together with other prognostic markers, determination of MMP-13 in ascitic fluid may help to identify patients at risk for early death and help to individualize adjuvant therapy. | |
| 540 | |a Copyright © 2003 by Walter de Gruyter GmbH & Co. KG | ||
| 690 | 7 | |a Biochemistry |2 nationallicence | |
| 690 | 7 | |a Molecular biology |2 nationallicence | |
| 690 | 7 | |a Cellular biology |2 nationallicence | |
| 700 | 1 | |a Hantke |D B. |4 aut | |
| 700 | 1 | |a Harbeck |D N. |4 aut | |
| 700 | 1 | |a Schmalfeldt |D B. |4 aut | |
| 700 | 1 | |a Claes |D I. |4 aut | |
| 700 | 1 | |a Hiller |D O. |4 aut | |
| 700 | 1 | |a Luther |D M.-O |4 aut | |
| 700 | 1 | |a Welk |D A. |4 aut | |
| 700 | 1 | |a Kuhn |D W. |4 aut | |
| 700 | 1 | |a Schmitt |D M. |4 aut | |
| 700 | 1 | |a Tschesche |D H. |4 aut | |
| 700 | 1 | |a Muehlenweg |D B. |4 aut | |
| 773 | 0 | |t Biological Chemistry |d Walter de Gruyter |g 384/8(2003-08-20), 1247-1251 |x 1431-6730 |q 384:8<1247 |1 2003 |2 384 |o bchm | |
| 856 | 4 | 0 | |u https://doi.org/10.1515/BC.2003.137 |q text/html |z Onlinezugriff via DOI |
| 908 | |D 1 |a research article |2 jats | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1515/BC.2003.137 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Hantke |D B. |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Harbeck |D N. |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Schmalfeldt |D B. |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Claes |D I. |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Hiller |D O. |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Luther |D M.-O |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Welk |D A. |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kuhn |D W. |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Schmitt |D M. |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Tschesche |D H. |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Muehlenweg |D B. |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Biological Chemistry |d Walter de Gruyter |g 384/8(2003-08-20), 1247-1251 |x 1431-6730 |q 384:8<1247 |1 2003 |2 384 |o bchm | ||
| 900 | 7 | |b CC0 |u http://creativecommons.org/publicdomain/zero/1.0 |2 nationallicence | |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-gruyter | ||